메뉴 건너뛰기




Volumn 83, Issue 6, 1998, Pages 1142-1152

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials

Author keywords

Advanced breast carcinoma; Anastrozole; Aromatase inhibitor; Megestrol acetate; Postmenopausal

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; MEGESTROL ACETATE;

EID: 0032530988     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.0.CO;2-5     Document Type: Article
Times cited : (473)

References (19)
  • 1
    • 0029741919 scopus 로고    scopus 로고
    • Aromatase inhibitors and breast cancer
    • Brodie AMH, Njar VCO. Aromatase inhibitors and breast cancer. Semin Oncol 1996;23(Suppl 9):10-20.
    • (1996) Semin Oncol , vol.23 , Issue.9 SUPPL. , pp. 10-20
    • Brodie, A.M.H.1    Njar, V.C.O.2
  • 2
    • 0029783837 scopus 로고    scopus 로고
    • Aromatase inhibitors in clinical practice: Current status and a look to the future
    • Harvey HA. Aromatase inhibitors in clinical practice: current status and a look to the future. Semin Oncol 1996;23(Suppl 9):33-8.
    • (1996) Semin Oncol , vol.23 , Issue.9 SUPPL. , pp. 33-38
    • Harvey, H.A.1
  • 3
    • 8944237006 scopus 로고    scopus 로고
    • Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials
    • Buzdar A, Jonat W, Howell A, Jones S-E, Blomqvist C, Vogel CL, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:2000-11.
    • (1996) J Clin Oncol , vol.14 , pp. 2000-2011
    • Buzdar, A.1    Jonat, W.2    Howell, A.3    Jones, S.-E.4    Blomqvist, C.5    Vogel, C.L.6
  • 4
    • 0029804714 scopus 로고    scopus 로고
    • Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in post-menopausal women with breast cancer
    • Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in post-menopausal women with breast cancer. Br J Cancer 1996;74:1286-91.
    • (1996) Br J Cancer , vol.74 , pp. 1286-1291
    • Geisler, J.1    King, N.2    Dowsett, M.3    Ottestad, L.4    Lundgren, S.5    Walton, P.6
  • 5
    • 0030040104 scopus 로고    scopus 로고
    • Arimidex (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers
    • Yates RA, Dowsett M, Fisher GV, Selen A, Wyld PJ. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996;73:543-8.
    • (1996) Br J Cancer , vol.73 , pp. 543-548
    • Yates, R.A.1    Dowsett, M.2    Fisher, G.V.3    Selen, A.4    Wyld, P.J.5
  • 6
    • 0031054095 scopus 로고    scopus 로고
    • A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma
    • Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1997;79:730-9.
    • (1997) Cancer , vol.79 , pp. 730-739
    • Buzdar, A.U.1    Jones, S.E.2    Vogel, C.L.3    Wolter, J.4    Plourde, P.5    Webster, A.6
  • 7
    • 9244245282 scopus 로고    scopus 로고
    • A randomized trial comparing two doses of the new selective aromatase inhibitor (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
    • Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, et al. A randomized trial comparing two doses of the new selective aromatase inhibitor (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32A:404-12.
    • (1996) Eur J Cancer , vol.32 A , pp. 404-412
    • Jonat, W.1    Howell, A.2    Blomqvist, C.3    Eiermann, W.4    Winblad, G.5    Tyrrell, C.6
  • 9
    • 0023708345 scopus 로고
    • The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
    • Howell A, Mackintosh J, Jones M, Redford J, Wagstaff J, Sellwood RA. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988;24:1567-72.
    • (1988) Eur J Cancer Clin Oncol , vol.24 , pp. 1567-1572
    • Howell, A.1    Mackintosh, J.2    Jones, M.3    Redford, J.4    Wagstaff, J.5    Sellwood, R.A.6
  • 11
    • 0029856576 scopus 로고    scopus 로고
    • Formestane: A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer
    • Wiseman LR, Goa KL. Formestane: a review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Drugs Aging 1996;9:292-306.
    • (1996) Drugs Aging , vol.9 , pp. 292-306
    • Wiseman, L.R.1    Goa, K.L.2
  • 12
    • 0029940269 scopus 로고    scopus 로고
    • Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma
    • Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Cancer 1996;77:2503-13.
    • (1996) Cancer , vol.77 , pp. 2503-2513
    • Buzdar, A.U.1    Smith, R.2    Vogel, C.3    Bonomi, P.4    Keller, A.M.5    Favis, G.6
  • 13
    • 0342595293 scopus 로고    scopus 로고
    • Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose effect and superiority of 2.5 mg letrozole over megestrol acetate (MA)
    • Smith I, Dombernowsky P, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose effect and superiority of 2.5 mg letrozole over megestrol acetate (MA) (Abstract PP-8-3|. Eur J Cancer 1996;32A: (Suppl 2):49.
    • (1996) Eur J Cancer , vol.32 A , Issue.2 SUPPL. , pp. 49
    • Smith, I.1    Dombernowsky, P.2    Falkson, G.3    Leonard, R.4    Panasci, L.5    Bellmunt, J.6
  • 14
    • 0003354802 scopus 로고    scopus 로고
    • Vorozole versus Megace in postmenopausal women with metastatic breast carcinoma who had relapsed following tamoxifen
    • Goss P, Wine E, Tannock I, Schwartz IH, Kremer AB, and study group. Vorozole versus Megace in postmenopausal women with metastatic breast carcinoma who had relapsed following tamoxifen [Abstract 542]. Proc ASCO 1997;16:155a.
    • (1997) Proc ASCO , vol.16
    • Goss, P.1    Wine, E.2    Tannock, I.3    Schwartz, I.H.4    Kremer, A.B.5
  • 15
    • 0000707927 scopus 로고    scopus 로고
    • Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with anti-estrogens
    • Marty M, Gershanovich M, Campos B, Romieu G, Lurie H, Bonaventura T, et al. Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with anti-estrogens [Abstract 544]. Proc ASCO 1997;16:156a.
    • (1997) Proc ASCO , vol.16
    • Marty, M.1    Gershanovich, M.2    Campos, B.3    Romieu, G.4    Lurie, H.5    Bonaventura, T.6
  • 16
    • 0000237541 scopus 로고    scopus 로고
    • Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen
    • Bergh J, Bonneterre J, Illiger HJ, Murray R, Nortier J, Paridaens R, et al. Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen [Abstract 543]. Proc ASCO 1997;16: 155a.
    • (1997) Proc ASCO , vol.16
    • Bergh, J.1    Bonneterre, J.2    Illiger, H.J.3    Murray, R.4    Nortier, J.5    Paridaens, R.6
  • 17
    • 0024041157 scopus 로고
    • Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - A phase III trial of the Piedmont Oncology Association
    • Muss HB, Wells B, Paschold EH, Black WR, Cooper MR, Capizzi RL, et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1988;6: 1098-106.
    • (1988) J Clin Oncol , vol.6 , pp. 1098-1106
    • Muss, H.B.1    Wells, B.2    Paschold, E.H.3    Black, W.R.4    Cooper, M.R.5    Capizzi, R.L.6
  • 18
    • 0025169549 scopus 로고
    • High- versus standard-dose megestrol acetate in women with advanced breast cancer: A phase III trial of the Piedmont Oncology Association
    • Muss HB, Case LD, Capizzi RL, Cooper MR, Cruz J, Jackson D, et al. High-versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1990;8:1797-805.
    • (1990) J Clin Oncol , vol.8 , pp. 1797-1805
    • Muss, H.B.1    Case, L.D.2    Capizzi, R.L.3    Cooper, M.R.4    Cruz, J.5    Jackson, D.6
  • 19
    • 0003299006 scopus 로고    scopus 로고
    • Efficacy of anastrozole (Arimidex) in a consecutive series of advanced breast cancer patients: M. D. Anderson Cancer Center (MDACC) experience
    • Michaud LB, Knoche AJ, Abbott B, Buzdar AU, Tashima C. Efficacy of anastrozole (Arimidex) in a consecutive series of advanced breast cancer patients: M. D. Anderson Cancer Center (MDACC) experience [Abstract 641]. Proc ASCO 1997; 16:183a.
    • (1997) Proc ASCO , vol.16
    • Michaud, L.B.1    Knoche, A.J.2    Abbott, B.3    Buzdar, A.U.4    Tashima, C.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.